DelveInsight’s Acute Coronary Syndrome market report provides a comprehensive understanding of the Acute Coronary Syndrome, historical and forecasted epidemiology, as well as Acute Coronary Syndrome market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).
Key Highlights from the Acute Coronary Syndrome Market Report
According to the American Heart Association, an estimated 5–8 million patients visit the emergency department each year for chest pain, with 20–25 percent being diagnosed with Acute Coronary Syndrome.
According to the findings of a study conducted by Ballerino et al. (2020), patients diagnosed with Acute Coronary Syndrome were statistically significantly older than those who did not have Acute Coronary Syndrome, with a higher prevalence of males.
Key players, such as Regeneron, Sanofi, DalCor Pharmaceutical, CSL Behring, and others are actively working towards the development of novel therapies for Acute Coronary Syndrome treatment.
The emerging therapies in the Acute Coronary Syndrome market include Alirocumab, Dalcetrapib, CSL112, and several others.
Dalcetrapib, the lead candidate of DalCor Pharmaceuticals, is a novel cholesterol ester transfer protein (CETP) inhibitor, a class of drugs that has been studied as a therapeutic to reduce the risk of cardiovascular events.
Alirocumab, which is being developed by Regeneron and Sanofi, has shown promising results in an Acute Coronary Syndrome trial.
For a better understanding of the disease, request for sample @ Acute Coronary Syndrome Market Outlook
The Acute Coronary Syndrome market report also offers comprehensive coverage of the current treatment practices, emerging drugs, Acute Coronary Syndrome market share of the individual therapies, current and forecasted Acute Coronary Syndrome market Size from 2018 to 2030 segmented by seven major markets.
Acute Coronary Syndrome: Overview
Acute Coronary Syndrome (ACS) is an umbrella term that refers to a group of conditions that are associated with acute myocardial ischemia and/or infarction and are typically caused by a sudden decrease in coronary blood flow. Myocardial infarction with ST-segment elevation (STEMI), which generally represents an acute total coronary occlusion, myocardial infarction without ST-segment elevation (NSTEMI), and unstable angina (UA), with or without myocardial injury, are the traditional types of Acute Coronary Syndrome.
Acute Coronary Syndrome Epidemiology Segmentation
The Acute Coronary Syndrome report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Acute Coronary Syndrome Incident Cases
Acute Coronary Syndrome Gender-Specific Incident Cases
Acute Coronary Syndrome Type-Specific Incident Cases
Acute Coronary Syndrome Diagnosed and Treatable Cases
Acute Coronary Syndrome Treatment Landscape
The current Acute Coronary Syndrome treatment is mainly based on antiplatelet therapy. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, and glycoprotein IIb/IIIa inhibitors are all well-established antiplatelet therapies used for Acute Coronary Syndrome treatment. Apart from this, some FDA-approved drugs such as Brilinta (AStraZeneca), Plavix (Sanofi-Aventis/Bristol-Myers Squibb), Ticagrelor (AstraZeneca), and Effient/Prasugrel (Eli Lilly and Company) are used to treat Acute Coronary Syndrome.
Acute Coronary Syndrome Market
Key pharmaceutical companies such as Regeneron, Sanofi, DalCor Pharmaceutical, CSL Behring, and others are expected to launch new therapies in the Acute Coronary Syndrome market.
The introduction of Alirocumab, Dalcetrapib, CSL112, and others are expected to give the Acute Coronary Syndrome market a significant boost in the forecast period 2021-30 in the 7MM.
Get a detailed analysis of the market @ Acute Coronary Syndrome Market Research
Acute Coronary Syndrome Pipeline Therapies and Key Companies
Alirocumab: Regeneron/ Sanofi
Dalcetrapib: DalCor Pharmaceuticals
CSL112: CSL Behring
Acute Coronary Syndrome Market Drivers
Increased market opportunity
Increasing Awareness
Increase in the number of research initiatives
Acute Coronary Syndrome Market Barriers
Diagnostic Delays
Lack of approved therapies
Chances of relapse
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Acute Coronary Syndrome Key Companies: Regeneron, Sanofi, DalCor Pharmaceutical, CSL Behring, among others.
Acute Coronary Syndrome Key Pipeline Therapies: Alirocumab, Dalcetrapib, CSL112, and others.
Acute Coronary Syndrome Segmentation: By Geography, By Acute Coronary Syndrome therapies
Analysis: Comparative and conjoint analysis of Acute Coronary Syndrome emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Report Introduction
2.
Acute Coronary Syndrome (ACS) : Market Overview at a Glance
3.
Disease Background and Overview: Acute Coronary Syndrome (ACS)
4.
Acute Coronary Syndrome Epidemiology and Patient Population
5.
Acute Coronary Syndrome (ACS) : Country-Wise Epidemiology
6.
Acute Coronary Syndrome United States Epidemiology
7.
Acute Coronary Syndrome EU–5 Countries Epidemiology
8.
Acute Coronary Syndrome Japan Epidemiology
9.
Acute Coronary Syndrome Treatments and Medical Practices
10.
Acute Coronary Syndrome Marketed Products
11.
Acute Coronary Syndrome Emerging Therapies
12.
Acute Coronary Syndrome (ACS) Market Size
13.
7MM Acute Coronary Syndrome (ACS) : Country-Wise Market Analysis
14.
Acute Coronary Syndrome United States Market Size
15.
Acute Coronary Syndrome EU5 Market Size
16.
Acute Coronary Syndrome Japan Market Size
17.
SWOT Analysis
18.
19.
20.
Acute Coronary Syndrome Market Access and Reimbursement
21.
Report Methodology
22.
DelveInsight Capabilities
23.
Disclaimer
24.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
Acute Respiratory Distress Syndrome Market
Get a comprehensive analysis of Acute Respiratory Distress Syndrome pipeline therapies and key companies such as Faron Pharmaceuticals, PhaseBio Pharmaceuticals, Sage Therapeutics, Chimerix, Direct Biologics, Kiniksa Pharmaceuticals, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/